Twelve patients given more than 1 year phenytoin monotherapy and 12 healthy control subjects taking no drugs and matched for sex and age were examined for polymorphonucleate (PMN) functions. To assess PMN activity, cell locomotion and directed migration, phagocytosing ability and bactericidal activity were investigated. No change either in the absolute or relative counts of PMN leucocytes was found in the patients. However, a significant impairment of both PMN chemotaxis and stimulated Nitro Blue Tetrazolium reduction or superoxide anion generation was observed in the patients as compared with the control group of subjects.
Get full access to this article
View all access options for this article.
References
1.
Aarli, J.A. & Gilhus, N.E. (1983). Antiepileptic drugs and resistance to infections . In Chronic Toxicity of Antiepileptic Drugs, eds J. Oxley, D. Janz & H. Meinardi, pp. 261-267. New York: Raven Press.
2.
Babior, B.M. (1978). Oxygen-dependent microbial killing by phagocytes . New Engl. J. Med., 298, 659-668.
3.
Baeher, A.W. (1976). The biochemical basis in Nitro Blue Tetrazolium reduction in normal human and chronic granulomatous disease PMN leucocytes . Blood, 48, 309-315.
4.
Boyum, A. (1968). Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 21 (Suppl. 97), 77-92.
5.
Gihlus, N.E. (1983). The in vitro effect of phenytoin and carbamazepine on subpopulations of human blood mononuclear cells. Int. J. Immunol., 5, 281-288.
6.
Gihlus, N.E., Matre, R. & Aarli, J.A. (1982). Lymphocyte subpopulations and lymphocyte function in phenytoin-treated patients with epilepsy. Int. J. Immunopharmacol. , 4, 43-48.
7.
Mac Kinney, A.A. & Booker, H.E. (1972). Diphenylidantoin effects on human lymphocytes in vitro and in vivo. Arch. Intern. Med., 129, 988-992.
8.
Marcoli, M., Gatti, G., Ippoliti, G., Lombardi, M., Crema, A., Zocchi, M.T., De Ponti, F., Lecchini, S. & Frigo, G.M. (1985). Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients. Human Toxicol., 4, 147-157.
9.
Mazzone, A., Ricevuti, G., Ricevuti, G.P., Castello, A., Coli, A. & Rizzo, S.C. (1985). Impaired neutrophil function in various hematological malignancies. Med. Biol. Environ., 13, 619-625.
10.
Ricevuti, G., Mazzone, A., Ricevuti, G.P., Rossi, M.L. & Rossini, S. (1984). Cytochemical and skin window studies in Polycythemia Rubra Vera. J. Clin. Hemat. Oncol., 14, 45-53.
11.
Seager, J., Jamison, D.L., Wilson, J., Hay-Ward, A.R. & Soothill, S.F. (1975). IgA deficiency, epilepsy, and phenytoin treatment. Lancet, ii, 632-635.
12.
Sorrell, T.C. & Forbes, I.J. (1975). Depression of immune competence by phenytoin and carbamazepine. Clin. Exp. Immunol., 20, 273-285.
13.
Webster, R.O., Goldstein, I.M. & Flick, M.R. (1984). Selective inhibition by phenytoin of chemotactic factor-stimulated neutrophil functions. J. Lab. Clin. Med. , 103, 22-33.
14.
Zygmond, S.H. & Hirsh, J.H. (1973). Leucocyte locomotion and chemotaxis: new methods for evaluation and demonstration of a cell-derived chemotactic factor. J. Exp. Med., 137, 387-410.
